MICAL2 and breast carcinoma: In particular, in breast cancer, cell migration is potentiated through maintaining epidermal growth factor receptor (EGFR) stability and activating EGFR/P38 signaling, whereas in gastric cancer cells the MICAL2/MRTF-A complex promotes migration through the CDC42 pathway [11].